Edition:
United Kingdom

Express Scripts Holding Co (ESRX.OQ)

ESRX.OQ on NASDAQ Stock Exchange Global Select Market

75.49USD
24 Apr 2018
Change (% chg)

$0.30 (+0.40%)
Prev Close
$75.19
Open
$75.63
Day's High
$76.29
Day's Low
$74.84
Volume
1,018,809
Avg. Vol
1,638,708
52-wk High
$85.05
52-wk Low
$55.80

Chart for

About

Express Scripts Holding Company is a pharmacy benefit management (PBM) company. The Company is engaged in providing healthcare management and administration services to its clients, including managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $36,015.96
Shares Outstanding(Mil.): 577.55
Dividend: --
Yield (%): --

Financials

  ESRX.OQ Industry Sector
P/E (TTM): 10.82 20.98 40.93
EPS (TTM): 5.76 -- --
ROI: 10.77 11.72 62.12
ROE: 22.51 13.91 73.69

Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

LOS ANGELES The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it.

24 Apr 2018

Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

LOS ANGELES The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc , Eli Lilly and Co and other makers of new migraine medicines to try and fix it.

24 Apr 2018

FOCUS-Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

LOS ANGELES, April 24 The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it.

24 Apr 2018

RPT-FOCUS-Express Scripts targets new migraine drugs to change U.S. pricing dynamic

LOS ANGELES, April 24 The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it.

24 Apr 2018

FOCUS-Express Scripts targets new migraine drugs to change U.S. pricing dynamic

LOS ANGELES, April 24 The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it.

24 Apr 2018

UPDATE 1-Glenview's Robbins says talk of Amazon's entering pharma is overblown

NEW YORK, April 23 Glenview Capital Management Chief Executive Larry Robbins said on Monday at the Sohn Investment Conference in New York that he still likes a trio of stocks he already owns, citing CVS Health Corp, McKesson Corp and Express Scripts Holdings.

23 Apr 2018

DoJ asks Cigna, Express Scripts for additional information

Cigna Corp said the U.S. Department of Justice has sought additional information from the company and Express Scripts in connection with the health insurer's ongoing $52 billion takeover of Express Scripts.

23 Apr 2018

BRIEF-Cigna-On April 23, Co, Express Scripts Each Received Request For Additional Info, Documentary Material From DOJ In Connection With DOJ's Review Of Deal

* CIGNA-ON APRIL 23, CO, EXPRESS SCRIPTS EACH RECEIVED REQUEST FOR ADDITIONAL INFO, DOCUMENTARY MATERIAL FROM DOJ IN CONNECTION WITH DOJ'S REVIEW OF DEAL

23 Apr 2018

DoJ asks Cigna, Express Scripts for additional information

April 23 Cigna Corp said the U.S. Department of Justice has sought additional information from the company and Express Scripts in connection with the health insurer's ongoing $52 billion takeover of Express Scripts.

23 Apr 2018

UnitedHealth earnings ease investor worries over flu season, stock up

UnitedHealth Group Inc , the largest U.S. health insurer, on Tuesday reassured investors that the pervasive flu season did not crimp first-quarter earnings as had been feared, boosting its shares as well as those of rivals.

17 Apr 2018

Competitors

Earnings vs. Estimates